공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

전이성 난소암 : 파이프라인 리뷰

Metastatic Ovarian Cancer - Pipeline Review, H2 2016

리서치사 Global Markets Direct
발행일 2016년 10월 상품 코드 253656
페이지 정보 영문 105 Pages
가격
US $ 2,000 ₩ 2,307,000 PDF (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,614,000 PDF (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 6,921,000 PDF (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


전이성 난소암 : 파이프라인 리뷰 Metastatic Ovarian Cancer - Pipeline Review, H2 2016
발행일 : 2016년 10월 페이지 정보 : 영문 105 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

전이성 난소암은 난소로부터 발생하는 암이지만, 신체의 다른 부위(횡격막, 장, 아래턱, 간, 폐 등)으로 전이됩니다. 피로, 조기 만복감, 복부 팽만, 다리 부종, 배변 습관의 변화, 배뇨 습관의 변화, 복통, 숨참 등의 증상을 볼 수 있습니다. 치료는 대부분 외과수술, 화학요법, 방사선요법이 병용됩니다.

전이성 난소암(Metastatic Ovarian Cancer)의 치료제 개발 상황에 대해 조사 분석했으며, 파이프라인 제품 개요, 임상시험 단계별 제품 개요, 주요 기업 개요, 치료제 개요, 파이프라인 제품의 최신 동향, 최신 뉴스와 프레스 릴리스 등의 정보를 전해드립니다.

서론

  • 조사 범위

전이성 난소암 개요

치료제 개발

  • 파이프라인 제품 개요
  • 파이프라인 제품 비교 분석

전이성 난소암 : 기업에서 개발중인 치료제

전이성 난소암 : 대학/기관에서 연구중인 치료제

전이성 난소암 : 파이프라인 제품 개요

  • 임상 단계 제품
  • 초기 단계 제품

전이성 난소암 : 기업에서 개발중인 제품

전이성 난소암 : 대학/기관에서 연구중인 제품

전이성 난소암 치료제 개발에 참여하고 있는 기업

  • Cellceutix Corporation
  • Eisai Co., Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Immune Design Corp.
  • Millennium Pharmaceuticals, Inc.
  • Natco Pharma Limited
  • Northwest Biotherapeutics, Inc.
  • Sumitomo Dainippon Pharma Co., Ltd.
  • VG Life Sciences, Inc.

전이성 난소암 : 치료제 평가

  • 단독치료 제품(Monotherapy Products)별
  • 병용 제품(Combination Products)별
  • 표적별
  • 작용기서별
  • 투여 경로별
  • 분자 종류별

치료제 개요

전이성 난소암 : 최근의 파이프라인 동향

전이성 난소암 : 휴지중인 프로젝트

전이성 난소암 : 개발이 중지된 제품

전이성 난소암 : 제품 개발 마일스톤

  • 주요 뉴스와 프레스 릴리스

부록

KSM 16.01.07

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Metastatic Ovarian Cancer - Pipeline Review, H2 2016, provides an overview of the Metastatic Ovarian Cancer (Oncology) pipeline landscape.

Metastatic ovarian cancer is a type of cancer that originates in the ovaries, but then spreads to other areas of the body, such as the diaphragm, intestine, mentum (a fatty layer that covers and pads abdominal organs), liver or lungs. Symptoms include fatigue, getting full quickly, abdominal swelling, leg swelling, changes in bowel habits, and changes in bladder habits, abdominal pain, and shortness of breath. Metastatic ovarian cancer is often treated with a combination of therapies that can include surgery, chemotherapy and radiation therapy.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Metastatic Ovarian Cancer - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Metastatic Ovarian Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Metastatic Ovarian Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Metastatic Ovarian Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 7, 9 and 2 respectively for Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 1 molecules, respectively for Metastatic Ovarian Cancer.

Metastatic Ovarian Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Metastatic Ovarian Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Metastatic Ovarian Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Metastatic Ovarian Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Metastatic Ovarian Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Metastatic Ovarian Cancer (Oncology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Metastatic Ovarian Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Metastatic Ovarian Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Metastatic Ovarian Cancer Overview
  • Therapeutics Development
    • Pipeline Products for Metastatic Ovarian Cancer - Overview
    • Pipeline Products for Metastatic Ovarian Cancer - Comparative Analysis
  • Metastatic Ovarian Cancer - Therapeutics under Development by Companies
  • Metastatic Ovarian Cancer - Therapeutics under Investigation by Universities/Institutes
  • Metastatic Ovarian Cancer - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Metastatic Ovarian Cancer - Products under Development by Companies
  • Metastatic Ovarian Cancer - Products under Investigation by Universities/Institutes
  • Metastatic Ovarian Cancer - Companies Involved in Therapeutics Development
    • Adgero Biopharmaceuticals Inc
    • Cellceutix Corporation
    • Eisai Co., Ltd.
    • F. Hoffmann-La Roche Ltd.
    • Immune Design Corp.
    • Millennium Pharmaceuticals Inc
    • MolMed S.p.A.
    • Natco Pharma Limited
    • Northwest Biotherapeutics, Inc.
    • Pfizer Inc.
    • Richter Gedeon Nyrt.
    • Sumitomo Dainippon Pharma Co., Ltd.
    • VG Life Sciences, Inc.
  • Metastatic Ovarian Cancer - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • Antisense RNAi Oligonucleotide to Replace MicroRNA-138 for Metastatic Ovarian Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • bevacizumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CMB-305 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • crizotinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DCVax-Direct - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DCVax-L - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • E-7449 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • emactuzumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • G-305 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • gedatolisib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • hydroxychloroquine + sorafenib tosylate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Kevetrin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LV-305 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NGR-hTNF - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NRCAN-019 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • orteronel - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OS-2966 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • REM-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SM-276001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Metastatic Ovarian Cancer - Dormant Projects
  • Metastatic Ovarian Cancer - Discontinued Products
  • Metastatic Ovarian Cancer - Product Development Milestones
    • Featured News & Press Releases
      • Jun 22, 2015: VG Life Sciences Granted Combination Cancer Drug Patent
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Metastatic Ovarian Cancer, H2 2016
  • Number of Products under Development for Metastatic Ovarian Cancer - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Metastatic Ovarian Cancer - Pipeline by Adgero Biopharmaceuticals Inc, H2 2016
  • Metastatic Ovarian Cancer - Pipeline by Cellceutix Corporation, H2 2016
  • Metastatic Ovarian Cancer - Pipeline by Eisai Co., Ltd., H2 2016
  • Metastatic Ovarian Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
  • Metastatic Ovarian Cancer - Pipeline by Immune Design Corp., H2 2016
  • Metastatic Ovarian Cancer - Pipeline by Millennium Pharmaceuticals Inc, H2 2016
  • Metastatic Ovarian Cancer - Pipeline by MolMed S.p.A., H2 2016
  • Metastatic Ovarian Cancer - Pipeline by Natco Pharma Limited, H2 2016
  • Metastatic Ovarian Cancer - Pipeline by Northwest Biotherapeutics, Inc., H2 2016
  • Metastatic Ovarian Cancer - Pipeline by Pfizer Inc., H2 2016
  • Metastatic Ovarian Cancer - Pipeline by Richter Gedeon Nyrt., H2 2016
  • Metastatic Ovarian Cancer - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2016
  • Metastatic Ovarian Cancer - Pipeline by VG Life Sciences, Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Metastatic Ovarian Cancer - Dormant Projects, H2 2016
  • Metastatic Ovarian Cancer - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Metastatic Ovarian Cancer, H2 2016
  • Number of Products under Development for Metastatic Ovarian Cancer - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top
전화 문의
F A Q